Estrogen receptor mutations and functional consequences for breast cancer

Trends in Endocrinology and Metabolism

Volumn 26, Issue 9, 2015, Pages 467-476

  Thomas, Christoforos ^a   Gustafsson, Jan Åke ^a  

^a University of Houston   (United States)

Author keywords

Breast cancer; Endocrine therapy; Estrogen receptor mutations; Metastasis; Resistance

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 1; ISOPROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BREAST CANCER; CLINICAL TRIAL (TOPIC); GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HORMONAL THERAPY; HUMAN; METASTASIS; MUTANT; POINT MUTATION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; BREAST NEOPLASMS; FEMALE; GENETICS; MUTATION;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MUTATION; RECEPTORS, ESTROGEN;

EID: 84940041611     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.06.007     Document Type: Review

References (80)

1. Kuiper G.G., et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:5925-5930.
2. Toft D., Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. U.S.A. 1966, 55:1574-1581.
3. Walter P., et al. Cloning of the human estrogen receptor cDNA. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:7889-7893.
4. Thomas C., Gustafsson J.A. The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer 2011, 11:597-608.
5. Britton D.J., et al. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat 2006, 96:131-146.
6. Yuan B., et al. A phosphotyrosine switch determines the antitumor activity of ERbeta. J. Clin. Invest. 2014, 124:3378-3390.
7. Hankinson S.E., et al. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004, 6:213-218.
8. Planas-Silva M.D., et al. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 2001, 61:3858-3862.
9. Hartman J., et al. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006, 66:11207-11213.
10. Samanta S., et al. Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene 2012, 31:4689-4697.
11. Thomas C., et al. ERbeta1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012, 14:R148.
12. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9:631-643.
13. Johnston S.R., Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 2003, 3:821-831.
14. Jeselsohn R., et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 2014, 20:1757-1767.
15. Barone I., et al. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin. Cancer Res. 2010, 16:2702-2708.
16. Fuqua S.A., et al. Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer Res. Treat. 2014, 144:11-19.
17. Hurtado A., et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008, 456:663-666.
18. Labhart P., et al. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1339-1344.
19. Osborne C.K., et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 2003, 95:353-361.
20. Honma N., et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol. 2008, 26:3727-3734.
21. Shaaban A.M., et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res. 2008, 14:5228-5235.
22. Shi L., et al. Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 2009, 27:3423-3429.
23. Roodi N., et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 1995, 87:446-451.
24. Karnik P.S., et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994, 54:349-353.
25. Zhang Q.X., et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997, 57:1244-1249.
26. Tremblay G.B., et al. Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res. 1998, 58:877-881.
27. White R., et al. Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO J. 1997, 16:1427-1435.
28. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
29. Banerji S., et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
30. Ellis M.J., et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
31. Stephens P.J., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404.
32. Merenbakh-Lamin K., et al. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013, 73:6856-6864.
33. Robinson D.R., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013, 45:1446-1451.
34. Toy W., et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45:1439-1445.
35. Brown L.A., et al. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:806-807.
36. Horlings H.M., et al. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:807-808.
37. Reis-Filho J.S., et al. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:809-810.
38. Poola I., Speirs V. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J. Steroid Biochem. Mol. Biol. 2001, 78:459-469.
39. Lee L.M., et al. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res. 2008, 28:479-483.
40. Wang Z., et al. A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9063-9068.
41. Chaudhri R.A., et al. Estrogen receptor-alpha 36 mediates the anti-apoptotic effect of estradiol in triple negative breast cancer cells via a membrane-associated mechanism. Biochim. Biophys. Acta 2014, 1843:2796-2806.
42. Chaudhri R.A., et al. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J. Biol. Chem. 2012, 287:7169-7181.
43. Deng H., et al. ER-alpha variant ER-alpha36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells. J. Steroid Biochem. Mol. Biol. 2014, 144:417-426.
44. Deng H., et al. ER-alpha36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. PLoS ONE 2014, 9:e88034.
45. Zhao Y., et al. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol. Med. 2011, 17:1233-1241.
46. Flouriot G., et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000, 19:4688-4700.
47. Marquez D.C., Pietras R.J. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001, 20:5420-5430.
48. Klinge C.M., et al. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Mol. Cell. Endocrinol. 2010, 323:268-276.
49. Erenburg I., et al. Loss of an estrogen receptor isoform (ER alpha delta 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol. Endocrinol. 1997, 11:2004-2015.
50. Huang B., et al. Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:1933-1938.
51. Marotti J.D., et al. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod. Pathol. 2010, 23:197-204.
52. Leung Y.K., et al. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13162-13167.
53. Zhao C., et al. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res. 2007, 67:3955-3962.
54. Rajapaksa G., et al. ERbeta decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. Oncogene 2014, Published online October 27, 2014. 10.1038/onc.2014.343.
55. Dhimolea E., et al. Estrogen receptors beta1 and beta2 are associated with distinct responses of estrogen receptor alpha-positive breast carcinoma to adjuvant endocrine therapy. Cancer Lett. 2015, 358:37-42.
56. Chantzi N.I., et al. Estrogen receptor beta2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions. J. Cancer Res. Clin. Oncol. 2014, 140:1057-1066.
57. Wimberly H., et al. ERbeta splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Res. Treat. 2014, 146:657-667.
58. Garcia T., et al. Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nucleic Acids Res. 1989, 17:8364.
59. Garcia T., et al. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol. Endocrinol. 1988, 2:785-791.
60. Lazennec G., et al. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Mol. Endocrinol. 1997, 11:1375-1386.
61. Weis K.E., et al. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol. 1996, 10:1388-1398.
62. Carlson K.E., et al. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 1997, 36:14897-14905.
63. Yu M., et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345:216-220.
64. Li S., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013, 4:1116-1130.
65. Nettles K.W., et al. NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat. Chem. Biol. 2008, 4:241-247.
66. Holst F., et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 2007, 39:655-660.
67. Chen J.R., et al. Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan. Virchows Arch. 2014, 464:689-699.
68. Vincent-Salomon A., et al. ESR1 gene amplification in breast cancer: a common phenomenon?. Nat. Genet. 2008, 40:809.
69. Nessling M., et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res. 2005, 65:439-447.
70. Pentheroudakis G., et al. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). PLoS ONE 2013, 8:e70634.
71. Fridlyand J., et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96.
72. Ooi A., et al. Gene amplification of ESR1 in breast cancers - fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J. Pathol. 2012, 227:8-16.
73. Moelans C.B., et al. ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous. PLoS ONE 2013, 8:e84189.
74. Jordan V.C., et al. Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. J. Natl. Cancer Inst. 2015, 107:djv075.
75. Shah S.P., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
76. Ingle J.N., et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol. 2006, 24:1052-1056.
77. Weir, H. et al. (2015) Discovery and pre-clinical pharmacology of AZD9496. An oral, selective estrogen receptor down-regulator (SERD). AACR Proceedings 2015, DDT01-03.
78. Dickler, M. et al. (2015) A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer. AACR Proceedings 2015, CT231.
79. Lai A., et al. Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J. Med. Chem. 2015, 58:4888-4904.
80. Fuqua S.A., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000, 60:4026-4029.